NCT02220738 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Alzheimer's Disease

Interventions

DRUG

ABT-957

ABT-957 administered twice-daily for 7 days

OTHER

Placebo for ABT-957

Placebo for ABT-957 administered twice-daily for 7 days

Trial Locations (4)

Site Reference ID/Investigator# 129641, New York

Site Reference ID/Investigator# 129435, Orlando

Site Reference ID/Investigator# 144825, Salt Lake City

Site Reference ID/Investigator# 129545, Glendale